2020
An Application of the Cure Model to a Cardiovascular Clinical Trial
Sevilimedu V, Ma S, Hartigan P, Kyriakides T. An Application of the Cure Model to a Cardiovascular Clinical Trial. Statistics In Biosciences 2020, 13: 402-430. DOI: 10.1007/s12561-020-09297-w.Peer-Reviewed Original ResearchMyocardial infarctionACS eventAggressive Drug Evaluation (COURAGE) trialClinical Outcomes Utilizing RevascularizationHazard of MICardiovascular clinical trialsDrug evaluation trialsCoronary syndromeClinical trialsMedical conditionsClinical practiceSurvival analysisCure modelNovel findingsRiskTrialsCured fractionEvaluation trialsRevascularizationInfarctionSyndrome
2017
Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia
Neocleous V, Fanis P, Toumba M, Phedonos AAP, Picolos M, Andreou E, Kyriakides TC, Tanteles GA, Shammas C, Phylactou LA, Skordis N. Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia. International Journal Of Endocrinology 2017, 2017: 8984365. PMID: 28487735, PMCID: PMC5405599, DOI: 10.1155/2017/8984365.Peer-Reviewed Original ResearchHeterozygous patientsNonclassic congenital adrenal hyperplasiaCategory of patientsCongenital adrenal hyperplasiaClinical hyperandrogenismHydroxyprogesterone levelsPhenotype-genotype correlationAdrenal hyperplasiaHigh riskAppropriate managementPatientsMild formFemale childrenHeterozygous mutationsHyperandrogenismSevere mutationsCYP21A2 geneHeterozygous femalesIdentification of variantsPresent studyFemalesRiskMutationsHyperandrogenaemiaHyperplasia